# Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)

> **NCT02633956** · PHASE2 · COMPLETED · sponsor: **Intercept Pharmaceuticals** · enrollment: 84 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** Obeticholic Acid
- **DRUG:** Atorvastatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02633956
- **Lead sponsor:** Intercept Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-04
- **Primary completion:** 2017-03-21
- **Final completion:** 2018-03-12
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2018-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02633956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02633956, "Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02633956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*